Ashwagandha root extract sustained-release (AshwaSR) reduces perceived stress and improves sleep quality in healthy stressed adults
In a randomized, double-blind, placebo-controlled trial, AshwaSR 150 mg and 300 mg capsules significantly reduced Perceived Stress Scale scores by 38.6% and 41.6% respectively from baseline to day 60 (P < .001). Both doses also significantly improved sleep quality, psychological well-being, and eating behavior compared to placebo, with the 300 mg dose additionally reducing serum cortisol levels (P < .05).
Evidence Score
Study Evidence
Study 1. Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial.
observationalThanawala S, Shah R, Alluri KV, Bhupathiraju K, Desomayanandanam P, Bhuvenendran A ยท Medicine (2026)
Result:
Mechanism Graph
Limitations
- โ Abstract does not report effect sizes or confidence intervals for sleep quality improvements
- โ Short duration (60 days) limits assessment of long-term efficacy and safety
- โ Single-center design may limit generalizability
Frequently Asked Questions
What is AshwaSR?โผ
AshwaSR is a sustained-release formulation of Ashwagandha root extract, tested at 150 mg and 300 mg once daily.
How much did stress levels decrease in the study?โผ
Perceived Stress Scale scores decreased by 38.6% in the 150 mg group and 41.6% in the 300 mg group over 60 days.
Did AshwaSR improve sleep quality?โผ
Yes, both doses significantly improved sleep quality compared to placebo (P < .001).
Was the supplement safe?โผ
No safety concerns were reported during the 60-day trial.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Thanawala S, Shah R, Alluri KV, Bhupathiraju K, Desomayanandanam P, Bhuvenendran A. "Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial.." Medicine, 2026. PMID: 41824889 DOI: 10.1097/MD.0000000000047990